- Home
- PPHC vs PROK Comparison
PPHC vs PROK Comparison
Compare PPHC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPHC | PROK |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.8M | 316.0M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PPHC | PROK |
|---|---|---|
| Price | $10.97 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 144.6K | ★ 1.2M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $186,541,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 24.72 | ★ 1075.00 |
| 52 Week Low | $7.01 | $1.30 |
| 52 Week High | $15.15 | $3.48 |
Technical Indicators
Market Signals| Indicator | PPHC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 41.05 |
| Support Level | $9.77 | $1.56 |
| Resistance Level | $11.78 | $2.01 |
| Average True Range (ATR) | 0.89 | 0.12 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 17.87 | 0.00 |
Price Performance
Historical ComparisonAbout PPHC Public Policy Holding Company Inc. Common Stock
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.